Replies to post #371999 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

And it is clear from the start, given the message to which I am replying, that NWBO measured from randomization as well, and then the below language certainly indicates not only that there is no change on that count, but that it will be consistent with the other trials:

https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/GB#summary

“The primary endpoint of this study is overall survival (OS) compared between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma.
E.5.1.1 Timepoint(s) of evaluation of this end point
October 2020
E.5.2 Secondary end point(s)
The first secondary endpoint is overall survival (OS) compared between patients randomized to placebo who received DCVax-L treatment following disease recurrence, and control patients from comparable, contemporaneous clinical trials, in patients with recurrent GBM.

The second secondary endpoint, confirmed progression-free survival (cPFS), is confirmed disease progression (cPD) compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.

The third secondary endpoint, PFS, is progression-free survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.

The fourth secondary objective, OS, is overall survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.

The fifth secondary objective is tumor response compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.“

Let’s be clear, it is the shorts who want to add 3 months or 6 weeks, kind of slides around, to NWBO’snumbers, but that makes no sense.

[sentiment_stocks]

I think the issue simply is that the interim DCVax-L blinded blended trial measured from surgery, hence, its KM curve was from surgery.

So when I overlaid the curve from that study on LL's latest chart with its various control arms, ex et al wanted the DCVax-L curve shifted to the left by 3 months to accommodate for the 3 month screening process that took place after surgery - when comparing that curve to the others. And when I shifted the DCVax-L interim blended treatment and control curve to the left by 3 months, it still beats the other curves.

I would be certain that when the final comparisons come out, the highly qualified stat people will have ensured that all curves will have an equal starting point.